Clinical Trials on Leukemia, Myeloid in Poland

Total 895 results

dr hab. n. med. Agnieszka Wierzbowska
Copernicus Memorial Hospital; Polish Adult Leukemia Group

Unknown

Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia (PALG-AML2012)

Acute Myeloid Leukemia

Poland
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Poland
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Acute Myeloid Leukemia

Italy, Poland
Maria Sklodowska-Curie National Research Institute...
KCRI

Not yet recruiting

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes (CLARA)

Acute Myeloid Leukemia Myelodysplastic Syndromes

Poland
Menarini Group
Medpace, Inc.; Theradex

Completed

SEL24/MEN1703 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Spain, Italy, Poland
Akinion Pharmaceuticals AB

Terminated

Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia

Acute Myeloid Leukemia

Sweden, Poland, Czech Republic, United Kingdom
Moleculin Biotech, Inc.

Recruiting

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Italy, Poland
Polish Adult Leukemia Group

Recruiting

A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old (PALG-AML1/2016)

Acute Myeloid Leukemia

United States, Poland
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Poland
OHSU Knight Cancer Institute
Oregon Health and Science University; Janssen, LP; The Leukemia and Lymphoma...

Terminated

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
OHSU Knight Cancer Institute
Ariad Pharmaceuticals

No longer available

Compassionate Use Ponatinib

Chronic Myeloid Leukemia | Philadelphia Chromosome Positive (Ph+) Leukemias

United States
BioLineRx, Ltd.
Genentech, Inc.

Terminated

A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Acute Myeloid Leukemia

Israel, Spain, United States, Czechia, Poland, Slovakia
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; Taiho Oncology, Inc.

Recruiting

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Brown University
Pfizer; The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Cornerstone Pharmaceuticals

Terminated

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Relapsed/Refractory Acute Myeloid Leukemia

United States, Spain, Korea, Republic of, France, Australia, Belgium, Austria, Germany, Poland
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia

France, Korea, Republic of, Spain, United Kingdom, Hungary, Poland
medac GmbH
Syneos Health; Celerion

Completed

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukaemias (ALL) | Acute Myeloid Leukaemias (AML) | Juvenile Myelomonocytic Leukaemias (JMML)

Germany, United Kingdom, Italy, Austria, Czechia, Poland
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
ImmunoGen, Inc.

Completed

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Brian Druker
AbbVie; Oregon Health and Science University; Incyte Corporation

Active, not recruiting

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Oryzon Genomics S.A.

Not yet recruiting

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
OHSU Knight Cancer Institute

Completed

MRI Assessment of Leukemia Response to Therapy

Acute Myelogenous Leukemia

United States
Chimerix

Completed

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute

Canada, United States, Poland, Switzerland, Germany
Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Gemin X

Completed

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

AML

United States, Canada
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Intellia Therapeutics

Terminated

Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, United Kingdom
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

Breast Cancer | Leukemia, Myeloid, Chronic

Poland
PETHEMA Foundation
Novartis

Completed

A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

Acute Myeloid Leukemia

Spain
Sumitomo Pharma America, Inc.

Terminated

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Acute Myeloid Leukemia (AML)

United States
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
Astex Pharmaceuticals, Inc.

Active, not recruiting

A Study of TAS1440 With ATRA in Subjects With r/r AML

Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
Takeda

Active, not recruiting

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

Acute Myeloid Leukemia (AML)

United States, France, Italy, Poland, Canada
Merus N.V.

Active, not recruiting

MCLA-117 in Acute Myelogenous Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Italy, Netherlands, Belgium, France
Daiichi Sankyo, Inc.

Completed

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (ACE)

Acute Myeloid Leukemia

United States, Spain, Netherlands, Canada, France, Germany, United Kingdom, Italy, Poland
K-Group Alpha, Inc., a wholly owned subsidiary...

Recruiting

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States
Jazz Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

High Risk Acute Myeloid Leukemia

United States, Canada
Helsinn Healthcare SA

Completed

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Beat AML, LLC

Recruiting

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Previously Untreated Acute Myeloid Leukemia

United States
Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
Novartis Pharmaceuticals

Active, not recruiting

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Acute Myeloid Leukemia

Italy, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States
Novartis Pharmaceuticals

Completed

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML (RADIUS)

Acute Myeloid Leukemia

United States, Canada
Seagen Inc.

Terminated

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)

Acute Myeloid Leukemia

Korea, Republic of, United States, Spain, Belgium, Germany, Czechia, Hungary, Taiwan, France, Israel, Italy, United Kingdom, Australia, Austria, Poland, Luxembourg
Gilead Sciences

Terminated

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) (ENTO in AML)

Acute Myeloid Leukemia

United States, Canada, Germany

Clinical Trials on Leukemia, Myeloid in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations